OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Lymphatic propagation of α-synuclein	518
Microglia, spreaders of Aβ seeds	313
Transmembrane protein interacts with α-synuclein to confer risk of PD	303
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	291
Ventricular enlargement caused by aducanumab	281
Brain stimulation aids walking after spinal injury	246
Refining oxytocin therapy for autism: context is key	242
Reply to ‘Perils and pitfalls of near-death experience research’	216
Global synergistic actions to improve brain health for human development	214
Neural cell state shifts and fate loss in ageing and age-related diseases	214
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	212
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	208
NODDI reveals brain microstructural changes in multiple sclerosis	202
Disease-specific modifications of tau protein	186
Continuous levodopa production by an artificial enzyme	185
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	179
Spinal muscular atrophy treatment in utero	174
Nir Giladi (1955–2024)	171
SEQUINS — a new initiative to address disparities in neurology	149
The impact of rare genetic variants on Alzheimer disease	142
Mitochondrial DNA instability in Huntington disease	136
The Digitized Memory Clinic	136
Study reveals new ALS risk genes	135
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	128
TREM2 mediates phagocytosis in glioblastoma	126

Microglia subset associated with high-grade glioma	125
Imperatives and co-benefits of research into climate change and neurological disease	120
The role of the gut microbiota in multiple sclerosis	115
Ultrasound lets gene therapy into the brain	108
Brain volume is associated with cognition in MS	107
Role for endogenous retrovirus in FTD	106
Amyloid plaques: hotspots for microglial turnover	104
Menopause influences tau pathology	104
Neurological care for LGBT+ people	103
Implications of AD plasma and PET biomarker discordance	102
Neuroinflammation predicts cognitive decline in FTD	100
Psychosis-causing lesions mapped to a hippocampal circuit	97
The challenges of anti-tau therapeutics in Alzheimer disease	96
MRI-based deep learning for TLE diagnosis	94
Brain imaging illuminates cognitive impairment in multiple sclerosis	93
Diversity, equity and inclusion in neurology	93
Author Correction: Viral pathogens increase risk of neurodegenerative disease	86
First trials test targeting of α-synuclein for Parkinson disease	85
Parkinson disease pathology can originate in the kidney	85
Gene therapy for seizures in focal cortical dysplasia	84
Precision neuroimmunology in multiple sclerosis — the horizon is near	83
α-Synuclein pathology as a target in neurodegenerative diseases	80
Management of freezing of gait — mechanism-based practical recommendations	80
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	77
APOE ε4 influences Parkinson disease progression	75
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	74
Challenges of combining multimodal data in assessment of people with traumatic brain injury	72
Food is brain medicine — relevance and translation to neurology	71
Evidence for altered astrocyte function in Duchenne muscular dystrophy	71
Neurosteroids alleviate seizures in rats	70
Glymphatic dysfunction in PD clinical progression	68
Thalamic inflammation — a therapeutic target for brain injury?	66
A new biological classification for Parkinson disease	66
Exosomal microRNA is promising biomarker in PD	64
Addressing disparities in neurology by building the workforce in LMICs	61
Ultrasound ablation treatment for PD	60